S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
WARNING: Mandatory U.S. Dollar Recall is Weeks Away (Ad)
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
WARNING: Mandatory U.S. Dollar Recall is Weeks Away (Ad)
Federal student loan payments are starting again. Here's what you need to know
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
WARNING: Mandatory U.S. Dollar Recall is Weeks Away (Ad)
A fight over precious groundwater in a rural California town is rooted in carrots
Indonesia is set to launch Southeast Asia's first high-speed railway, largely funded by China
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
WARNING: Mandatory U.S. Dollar Recall is Weeks Away (Ad)
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
WARNING: Mandatory U.S. Dollar Recall is Weeks Away (Ad)
Federal student loan payments are starting again. Here's what you need to know
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
WARNING: Mandatory U.S. Dollar Recall is Weeks Away (Ad)
A fight over precious groundwater in a rural California town is rooted in carrots
Indonesia is set to launch Southeast Asia's first high-speed railway, largely funded by China
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
WARNING: Mandatory U.S. Dollar Recall is Weeks Away (Ad)
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
WARNING: Mandatory U.S. Dollar Recall is Weeks Away (Ad)
Federal student loan payments are starting again. Here's what you need to know
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
WARNING: Mandatory U.S. Dollar Recall is Weeks Away (Ad)
A fight over precious groundwater in a rural California town is rooted in carrots
Indonesia is set to launch Southeast Asia's first high-speed railway, largely funded by China
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
WARNING: Mandatory U.S. Dollar Recall is Weeks Away (Ad)
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
WARNING: Mandatory U.S. Dollar Recall is Weeks Away (Ad)
Federal student loan payments are starting again. Here's what you need to know
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
WARNING: Mandatory U.S. Dollar Recall is Weeks Away (Ad)
A fight over precious groundwater in a rural California town is rooted in carrots
Indonesia is set to launch Southeast Asia's first high-speed railway, largely funded by China
NASDAQ:AUPH

Aurinia Pharmaceuticals (AUPH) Stock Forecast, Price & News

$7.77
-0.11 (-1.40%)
(As of 09/29/2023 ET)
Compare
Today's Range
$7.65
$7.98
50-Day Range
$7.77
$12.27
52-Week Range
$4.07
$12.43
Volume
2.33 million shs
Average Volume
1.83 million shs
Market Capitalization
$1.11 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.33

Aurinia Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
71.6% Upside
$13.33 Price Target
Short Interest
Bearish
11.86% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.53mentions of Aurinia Pharmaceuticals in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.58) to ($0.27) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.59 out of 5 stars

Medical Sector

886th out of 972 stocks

Pharmaceutical Preparations Industry

414th out of 449 stocks


AUPH stock logo

About Aurinia Pharmaceuticals (NASDAQ:AUPH) Stock

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. The company also offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.

AUPH Price History

AUPH Stock News Headlines

Biden's Digital Dollar Nightmare
On July 20th, 2023, the Federal Reserve launched FedNow, which could spark the fuse for a Digital Dollar. If a Digital Dollar happens, the government could: Monitor every transaction, keep track of your spending habits, and potentially control your individual choices… Which MAY steal your freedoms in one way or another. And if you don’t plan for this now... Your retirement savings could be at risk of being frozen, hacked, or deleted. You’ll want to act fast... Because with Biden’s long history of voting against Americans... Who knows how much longer until Biden strikes again! Get your hands on this FREE Wealth Protection Kit today and learn how you could shield your savings and investments before it’s too late!
Biden's Digital Dollar Nightmare
On July 20th, 2023, the Federal Reserve launched FedNow, which could spark the fuse for a Digital Dollar. If a Digital Dollar happens, the government could: Monitor every transaction, keep track of your spending habits, and potentially control your individual choices… Which MAY steal your freedoms in one way or another. And if you don’t plan for this now... Your retirement savings could be at risk of being frozen, hacked, or deleted. You’ll want to act fast... Because with Biden’s long history of voting against Americans... Who knows how much longer until Biden strikes again! Get your hands on this FREE Wealth Protection Kit today and learn how you could shield your savings and investments before it’s too late!
Aurinia Pharmaceuticals (AUPH) Gets a Buy from RBC Capital
Nasdaq EM Asia Utilities Large
See More Headlines
Receive AUPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aurinia Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AUPH Company Calendar

Last Earnings
8/03/2023
Today
10/01/2023
Next Earnings (Estimated)
11/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AUPH
Employees
300
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$13.33
High Stock Price Forecast
$15.00
Low Stock Price Forecast
$12.00
Forecasted Upside/Downside
+71.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$-108,180,000.00
Pretax Margin
-44.42%

Debt

Sales & Book Value

Annual Sales
$134.03 million
Book Value
$2.85 per share

Miscellaneous

Free Float
137,255,000
Market Cap
$1.11 billion
Optionable
Optionable
Beta
1.24
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Mr. Peter S. Greenleaf M.B.A. (Age 53)
    Pres, CEO & Director
    Comp: $1.34M
  • Mr. Joseph M. Miller CPAMr. Joseph M. Miller CPA (Age 49)
    Chief Financial Officer
    Comp: $791.92k
  • Mr. Matthew Maxwell Donley M.B.A.Mr. Matthew Maxwell Donley M.B.A. (Age 54)
    Exec. VP of Operations & Strategy
    Comp: $811.82k
  • Mr. Stephen P. Robertson (Age 41)
    Exec. VP, Gen. Counsel, Corp. Sec. & Chief Compliance Officer
    Comp: $739.68k
  • Dr. Volker Knappertz D.Sc. (Age 58)
    M.D., Exec. VP of R&D
    Comp: $742.85k
  • Mr. James Archie Harrell Jr. (Age 53)
    Head of Investor Relations
  • Mr. Fran Lynch
    VP of Sales
  • Mr. Michael R. MartinMr. Michael R. Martin (Age 51)
    Chief Bus. Officer
  • Ms. Sue Evans
    Sr. VP of Global Regulatory Affairs
  • Mr. Scott Habig (Age 63)
    Chief Commercial Officer













AUPH Stock - Frequently Asked Questions

Should I buy or sell Aurinia Pharmaceuticals stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aurinia Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" AUPH shares.
View AUPH analyst ratings
or view top-rated stocks.

What is Aurinia Pharmaceuticals' stock price forecast for 2023?

4 brokers have issued 1-year price objectives for Aurinia Pharmaceuticals' shares. Their AUPH share price forecasts range from $12.00 to $15.00. On average, they expect the company's share price to reach $13.33 in the next twelve months. This suggests a possible upside of 71.6% from the stock's current price.
View analysts price targets for AUPH
or view top-rated stocks among Wall Street analysts.

How have AUPH shares performed in 2023?

Aurinia Pharmaceuticals' stock was trading at $4.32 at the beginning of the year. Since then, AUPH shares have increased by 79.9% and is now trading at $7.77.
View the best growth stocks for 2023 here
.

Are investors shorting Aurinia Pharmaceuticals?

Aurinia Pharmaceuticals saw a increase in short interest in September. As of September 15th, there was short interest totaling 17,010,000 shares, an increase of 21.8% from the August 31st total of 13,960,000 shares. Based on an average daily volume of 2,180,000 shares, the short-interest ratio is presently 7.8 days.
View Aurinia Pharmaceuticals' Short Interest
.

When is Aurinia Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our AUPH earnings forecast
.

How were Aurinia Pharmaceuticals' earnings last quarter?

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) released its quarterly earnings results on Thursday, August, 3rd. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.20) by $0.12. The biotechnology company had revenue of $41.49 million for the quarter, compared to analyst estimates of $37.90 million. Aurinia Pharmaceuticals had a negative trailing twelve-month return on equity of 18.05% and a negative net margin of 45.42%. The business's revenue was up 47.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.25) earnings per share.

What ETFs hold Aurinia Pharmaceuticals' stock?

ETFs with the largest weight of Aurinia Pharmaceuticals (NASDAQ:AUPH) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP).ALPS Medical Breakthroughs ETF (SBIO).

What guidance has Aurinia Pharmaceuticals issued on next quarter's earnings?

Aurinia Pharmaceuticals updated its FY 2023 earnings guidance on Thursday, August, 3rd. The company provided EPS guidance of for the period. The company issued revenue guidance of $150.00 million-$160.00 million, compared to the consensus revenue estimate of $154.35 million.

What other stocks do shareholders of Aurinia Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aurinia Pharmaceuticals investors own include Tetraphase Pharmaceuticals (TTPH), NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), Sorrento Therapeutics (SRNE), Cara Therapeutics (CARA), Exelixis (EXEL), AbbVie (ABBV), Amarin (AMRN) and Array Technologies (ARRY).

What is Aurinia Pharmaceuticals' stock symbol?

Aurinia Pharmaceuticals trades on the NASDAQ under the ticker symbol "AUPH."

How do I buy shares of Aurinia Pharmaceuticals?

Shares of AUPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aurinia Pharmaceuticals' stock price today?

One share of AUPH stock can currently be purchased for approximately $7.77.

How much money does Aurinia Pharmaceuticals make?

Aurinia Pharmaceuticals (NASDAQ:AUPH) has a market capitalization of $1.11 billion and generates $134.03 million in revenue each year. The biotechnology company earns $-108,180,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis.

How many employees does Aurinia Pharmaceuticals have?

The company employs 300 workers across the globe.

How can I contact Aurinia Pharmaceuticals?

Aurinia Pharmaceuticals' mailing address is 4464 MARKHAM STREET SUITE 1203, VICTORIA A1, V8Z 7X8. The official website for the company is www.auriniapharma.com. The biotechnology company can be reached via phone at 250-708-4272, via email at ir@auriniapharma.com, or via fax at 250-744-2498.

This page (NASDAQ:AUPH) was last updated on 10/1/2023 by MarketBeat.com Staff

My Account -